Jocet Active tablets, No. 20

Jocet Active tablets, No. 20; 'As part of the combined therapy of acute and chronic bronchopulmonary diseases, accompanied by the formation of difficult-to-separate viscous secretions: tracheobronchitis; acute and chronic bronchitis; chronic obstructive pulmonary disease (COPD); bronchial asthma; pneumonia; pulmonary emphysema; whooping cough; pneumoconiosis; pulmonary tuberculosis.

Inside Adults and children over 18 years of age are prescribed 1 tablet 3 times / day.

1 tab.

ambroxol hydrochloride 30 mg

guaifenesin 100 mg

salbutamol sulfate 2.4 mg,?

which corresponds to the content of salbutamol 2 mg

Hypersensitivity to the components of the product; pregnancy, breastfeeding period; tachycardia, myocarditis, heart defects (including aortic stenosis); arterial hypertension; decompensated diabetes mellitus, hyperthyroidism, glaucoma; hepatic and / or renal failure; peptic ulcer of the stomach and duodenum in the acute stage, gastric bleeding; children under 18 years of age.

With care: diabetes mellitus, severe diseases of the cardiovascular system (including coronary artery disease, chronic heart failure), pheochromocytoma, gastric ulcer and duodenal ulcer in remission, impaired motor function of the bronchi and increased mucus secretion (for example, in rare syndrome of primary ciliary dyskinesia).

pharmachologic effect

Combined remedy, the action of which is due to the properties of its constituent components. Ambroxol is a mucolytic agent. Increases the serous component of bronchial secretions, enhances the formation of pulmonary surfactant and activates the cilia of the ciliated epithelium, thereby providing an expectorant effect of the agent: reducing the viscosity of sputum, increasing its volume and improving discharge. Guaifenesin reduces the surface tension and adhesive properties of sputum, stimulates secretory cells of the bronchial mucosa, producing neutral polysaccharides, depolymerizes acidic mucopolysaccharides, reduces the viscosity of sputum, activates the ciliary apparatus of the bronchi, facilitates the removal of sputum and promotes the transition of an unproductive cough into a productive one. Salbutamol - bronchodilator,is a selective beta-2-adrenergic agonist. In therapeutic doses, it acts on the beta-2-adrenergic receptors of the smooth muscles of the bronchi, preventing and / or eliminating bronchial spasm, thereby reducing the resistance in the airways and increasing the vital capacity of the lungs. The brokhoraeshiruyuschee effect of salbutamol (with reversible airway obstruction) lasts from 4 to 6 hours.

Pharmacokinetics

Ambroxol Ambroxol is characterized by rapid and almost complete absorption from the gastrointestinal tract with a linear dose dependence in the therapeutic range of concentrations. Cmax when taken orally is achieved after 1 - 2.5 hours. Vd is 552 liters. In the therapeutic concentration range, plasma protein binding is approximately 90%. The highest concentrations of ambroxol are found in the lungs. It is metabolized in the liver, mainly by glucuronidation and by partial cleavage to dibromantranilic acid (approximately 10%), as well as a small amount of additional metabolites. T1 / 2 of ambroxol is 10 hours. Excreted by the kidneys: 83% of the dose taken. Guaifenesin Absorption from the gastrointestinal tract is fast and is 25-30 minutes after ingestion. T1 / 2 is 1 hour. Penetrates into tissues containing acidic mucopolysaccharides.Approximately 60% is metabolized in the liver. It is excreted by the lungs (with sputum) and kidneys both unchanged and in the form of inactive metabolites. Salbutamol When taken orally, absorption is high, bioavailability is about 50%. Food intake reduces the rate of absorption, but does not affect bioavailability. Plasma protein binding - 10%. Penetrates the placental barrier. Salbutamol is absorbed from the gastrointestinal tract and undergoes first-pass metabolism in the liver, turning into phenolic sulfate. T1 / 2 - 3.8-6 hours. Unchanged salbutamol and the metabolite are excreted, mainly by the kidneys (69-90%).Plasma protein binding - 10%. Penetrates the placental barrier. Salbutamol is absorbed from the gastrointestinal tract and undergoes first-pass metabolism in the liver, turning into phenolic sulfate. T1 / 2 - 3.8-6 hours Unchanged salbutamol and the metabolite are excreted, mainly by the kidneys (69-90%).Plasma protein binding - 10%. Penetrates the placental barrier. Salbutamol is absorbed from the gastrointestinal tract and undergoes first-pass metabolism in the liver, turning into phenolic sulfate. T1 / 2 - 3.8-6 hours. Unchanged salbutamol and the metabolite are excreted, mainly by the kidneys (69-90%).

Side effect

From the immune system: rarely - hypersensitivity reactions, skin rash, urticaria; frequency unknown - anaphylactic reactions, incl. anaphylactic shock, angioedema, pruritus. From the nervous system: rarely - headache, dizziness, increased nervous irritability, sleep disturbances, drowsiness, tremors, convulsions. From the side of the cardiovascular system: rarely - tachycardia, decreased blood pressure, peripheral vasodilation, collapse; frequency unknown - myocardial ischemia. From the respiratory system: rarely - bronchospasm (as a sign of a hypersensitivity reaction). From the digestive system: rarely - nausea, vomiting, diarrhea, abdominal pain, exacerbation of gastric ulcer and duodenal ulcer. From the urinary system: rarely - it is possible to stain the urine pink.On the part of the skin and subcutaneous tissues: frequency unknown - severe skin adverse reactions, incl. erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis. From the side of metabolism: rarely - hypokalemia, hyperglycemia.

Application during pregnancy and lactation

Use during pregnancy and breastfeeding is contraindicated.

Application for violations of liver function

Use in liver failure is contraindicated.

Application for impaired renal function

Use in renal failure is contraindicated.

Application in children

Contraindicated for use in children and adolescents under the age of 18 years.

special instructions

Patients with severe heart disease (eg, coronary artery disease, tachyarrhythmia, or severe heart failure) receiving salbutamol should be warned to seek medical attention if they develop symptoms of an exacerbated heart disease. There have been reports of severe skin reactions such as erythema multiforme, Stevens-Johnson syndrome (STS), toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (OGEP) associated with the use of ambroxol. If symptoms of a progressive skin reaction occur (sometimes associated with damage to the mucous membranes of the mouth, throat, nose, eyes, genitals), you should immediately stop taking the drug and consult a doctor. It is not recommended to use alkaline solutions simultaneously with this agent.Caution should be exercised when prescribing this remedy for violations of liver and / or kidney function. Influence on the ability to drive vehicles and control mechanisms Given the possibility of the development of such phenomena as dizziness, drowsiness, tachycardia, hand tremors against the background of the use of this drug, during the period of its use, one should refrain from driving vehicles and mechanisms, as well as performing other work that requires concentration of attention and speed of psychomotor reactions.during the period of its application, one should refrain from driving vehicles and mechanisms, as well as performing other work that require concentration of attention and speed of psychomotor reactions.during the period of its use, one should refrain from driving vehicles and mechanisms, as well as performing other work that require concentration of attention and speed of psychomotor reactions.

Drug interactions

Ambroxol, which is part of the drug, increases the penetration of amoxicillin, cefuroxime, and erythromycin into the bronchial secretions. When used simultaneously with theophylline, the latter enhances the effect and increases the likelihood of developing side effects of salbutamol, which is part of the drug. Diuretics and GCS drugs enhance the hypokalemic effect of salbutamol. This remedy is not prescribed concurrently with drugs containing codeine and other antitussives, as this makes it difficult for the liquefied sputum to pass. Tricyclic antidepressants, thyroid hormones, MAO inhibitors increase the risk of complications from the cardiovascular system. This agent reduces the activity of beta-blockers, antihypertensive and antianginal drugs.This remedy increases the likelihood of digitalis intoxication.

'